Navigation Links
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Date:11/1/2007

ibit angiogenesis in diseased conditions, without, importantly, affecting normal blood vessels in healthy tissues.

These findings pave the way for the development of a new class of improved cancer therapeutics which could have a complementary mechanism of action and potentially enhanced safety profile in comparison to existing angiogenesis inhibitors.

Angiogenesis inhibitors are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutriments. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. Currently available angiogenesis inhibitors specifically target vascular endothelial growth factor (VEGF), which plays an important role in promoting the formation of blood vessels. However, since VEGF inhibitors also act on healthy tissue, their therapeutic potential is hampered by side effects. Although PlGF is a homologue of VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue.

Based on its anti-angiogenic properties, ThromboGenics and BioInvent also intend to develop TB-403 for eye diseases, to block uncontrolled blood vessel growth in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commented: "Today's publication in the prestigious journal Cell clearly highlights our ground-breaking research in the field of angiogenesis. The data in the Cell paper shows the potential of our novel anti-PlGF antibody, TB-403, based on its unique ability to block the development of new blood vessels, but only via mechanisms that exist in the diseased state. This mode of action, which is different from and complementary to current anti-VEGF inhibitors, makes it attractive as both a stand-alone and combination therapy. I am very excited that we w
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 Ed Bilsky, Ph.D., ... the Center for Excellence in the Neurosciences (CEN), and ... has been selected as a member of the prestigious ... first neuroscientist from Maine to receive this honor. , ... supported entirely by the Dana Foundation. Its mission ...
(Date:12/19/2014)... 19, 2014 In contrast to traditional ... with various colors, Valoya uses proprietary LED technology to ... best possible uniformity which is critical in low proximity ... spectral accuracy throughout its lifetime which is up to ... , "The investment cost was clearly higher when ...
(Date:12/19/2014)...  Decision Resources Group finds that the ... moderately through 2023 as the aging population, increasing adoption ... biomaterials all spur procedure volumes. Growth will be particularly ... and India , where ... for a larger proportion of the population. ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... ... to organizations representing the best web sites dedicated to health care. , ... Boston, Mass. (PRWEB) November 10, ... fifth consecutive eHealthcare Leadership Award and seventh overall at the 10th Annual Healthcare Internet ...
... ... of its annual Student Award Program , ... Boston, Mass. (Vocus) -- The Adventus Group , a ... University of Massachusetts Amherst to recognize emerging environmental scientists during the 25th Annual International ...
... , NEW YORK, Nov. 9 "Micro cap and small cap ... and exposure as a ,buying window, opens and to take advantage ... metals," states Herbert Haft, President of The Haft Group, Inc, Manhattan ... and small cap equities market in the US and Canada, and ...
Cached Biology Technology:CenterWatch Honored a Fifth Consecutive Year for Best Healthcare Content 2University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders 2University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders 3University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders 4Haft Group says Bullish Commodity Market Triggers Small and Micro-cap Upsurge 2
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... (April 17, 2011) Michael Croft, Ph.D., a researcher ... has discovered a molecule,s previously unknown role as a ... making the molecule a promising therapeutic target for chronic ... lung conditions. A scientific paper on Dr. Croft,s ...
... WASHINGTON, D.C. April 14, 2011 ... Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) ... multiforme (GBM) brain tumors, following tumor recurrence after ... an anti-mitotic, anti-cancer therapy as patients maintain their ...
... of the world,s two best-loved flavours and demand for it ... the global food industry could be more secure, thanks to ... is a compound that comes from the vanilla bean, the ... tropical, climbing vine originally cultivated by ancient Central American civilisations ...
Cached Biology News:La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 2La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 3FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2Preserving a world favorite flavour 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... feature for easy storage. Linkage: This CLS number ... match Cornings product number. If showing no availability ... (Z70,947-6) or contact customer service for assistance. ID ... area 55 cm 2 D H ...
... Description: ,Kit containing Dermal Fibroblasts ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ... ,Source: Dermis, mouse/BalbC, embryonic day 18.5 ...
...
Biology Products: